Bromocriptine treatment of women with suspected pituitary prolactin-secreting microadenomas.
The present study was designed to investigate the efficacy of bromocriptine in reducing serum prolactin (PRL) levels and in decreasing the size of PRL-secreting microadenomas. Bromocriptine, 5.0 mg, was administered daily for 2 years of 17 women who had galactorrhea, hyperprolactinemia, and hypocycloidal polytomographic evidence suggestive of a pituitary microadenoma. Serum PRL levels were normalized in 16 of 17 women during therapy. Associated with this was resumption of regular menses in 15 of 16 women with menstrual dysfunction and cessation of galactorrhea in 16 of the 17 women. Improvement in the roentgenographic appearance of the sella turcica occurred in two women. No progression in tumor size was found during the course of therapy. Side effects attributed to bromocriptine were minimal, transient, and usually well tolerated. These data suggest that bromocriptine is an appropriate therapeutic modality for PRL-secreting pituitary microadenomas.
D000236:Adenoma / Q000188:drug therapy* / Q000378:metabolism; D000293:Adolescent; D000328:Adult; D001971:Bromocriptine / Q000008:administration & dosage*; D004341:Drug Evaluation; D005260:Female; D005687:Galactorrhea / Q000188:drug therapy; D006801:Humans; D008599:Menstruation Disturbances / Q000188:drug therapy; D008875:Middle Aged; D010911:Pituitary Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D011247:Pregnancy; D011388:Prolactin / Q000097:blood / Q000378:metabolism*; D011859:Radiography; D012658:Sella Turcica / Q000000981:diagnostic imaging
D001971:Bromocriptine; D011388:Prolactin